Advances in the DNA Nanotechnology for the Cancer Biomarkers Analysis: Attributes and Applications

Semin Cancer Biol. 2022 Nov;86(Pt 2):1105-1119. doi: 10.1016/j.semcancer.2021.12.012. Epub 2022 Jan 1.

Abstract

The most commonly used clinical methods are enzyme-linked immunosorbent assay (ELISA) and quantitative PCR (qPCR) in which ELISA was applied for the detection of protein biomarkers and qPCR was especially applied for nucleic acid biomarker analysis. Although these constructed methods have been applied in wide range, they also showed some inherent shortcomings such as low sensitivity, large sample volume and complex operations. At present, many methods have been successfully constructed on the basis of DNA nanotechnology with the merits of high accuracy, rapid and simple operation for cancer biomarkers assay. In this review, we summarized the bioassay strategies based on DNA nanotechnology from the perspective of the analytical attributes for the first time and discussed and the feasibility of the reported strategies for clinical application in the future.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor* / analysis
  • DNA
  • Enzyme-Linked Immunosorbent Assay / methods
  • Humans
  • Nanotechnology / methods
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics
  • Neoplasms* / metabolism

Substances

  • Biomarkers, Tumor
  • DNA
  • Biomarkers